Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia
Open Access
- 1 April 2003
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 60 (4) , 365-368
- https://doi.org/10.1001/archpsyc.60.4.365
Abstract
THE USE of placebo control in clinical trials is associated with ethical problems, especially in cases where effective treatment is available and where progressive disease involves potential deterioration that is likely to be irreversible.1,2 Yet, in Europe, granting a license for the indication of schizophrenia depends on demonstration of efficacy in comparison "in principle" with placebo.3Keywords
This publication has 5 references indexed in Scilit:
- Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration DatabaseAmerican Journal of Psychiatry, 2001
- Suicide Risk in Placebo-Controlled Studies of Major DepressionAmerican Journal of Psychiatry, 2001
- Reduction of suicidality during clozapine treatment of neuroleptic- resistant schizophrenia: impact on risk-benefit assessmentAmerican Journal of Psychiatry, 1995
- The Continuing Unethical Use of Placebo ControlsNew England Journal of Medicine, 1994
- Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophreniaAmerican Journal of Psychiatry, 1994